CoChat
Cited by 214

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications

Open access
Gonzalez-Ortiz, Fernando, Kac, Przemysław R., Brum, Wagner S., Zetterberg, Henrik, Blennow, Kaj, Karikari, Thomas K. · 2023 · Molecular Neurodegeneration

Abstract

As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected individuals, their families and caregivers, and healthcare systems. Although AD can be identified and diagnosed by cerebrospinal fluid or neuroimaging biomarkers that concord with neuropathological evidence and clinical symptoms, challenges regarding practicality and accessibility hinder their widespread availability and implementation. Consequently, many people with suspected cognitive impairment due to AD do not receive a biomarker-supported diagnosis. Blood biomarkers have the capacity to help expand access to AD diagnostics worldwide. One such promising biomarker is plasma phosphorylated tau (p-tau), which has demonstrated specificity to AD versus non-AD neurodegenerative diseases, and will be extremely important to inform on clinical diagnosis and eligibility for therapies that have recently been approved. This review provides an update on the diagnostic and prognostic performances of plasma p-tau181, p-tau217 and p-tau231, and their associations with in vivo and autopsy-verified diagnosis and pathological hallmarks. Additionally, we discuss potential applications and unanswered questions of plasma p-tau for therapeutic trials, given their recent addition to the biomarker toolbox for participant screening, recruitment and during-trial monitoring. Outstanding questions include assay standardization, threshold generation and biomarker verification in diverse cohorts reflective of the wider community attending memory clinics and included in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-023-00605-8

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 214

Metadata

Authors
Gonzalez-Ortiz, F., Kac, P. R., Brum, W. S., Zetterberg, H., Blennow, K., & Karikari, T. K.
Venue
Molecular Neurodegeneration
Published
2023-03-16
Volume
18
Issue
1
Pages
18-18
ISSN
1750-1326 (ISSN-L)
OpenAlex
W4327582360
Cited by
214
References
50
FWCI
38.29
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications. https://app.cochat.ai/papers/10.1186/s13024-023-00605-8
The paper
Gonzalez-Ortiz, F., Kac, P. R., Brum, W. S., Zetterberg, H., Blennow, K., & Karikari, T. K. (2023). Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-023-00605-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.